Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

HIV dynamics studies, based on differential equations, have significantly improved the knowledge on HIV infection. While first studies used simplified short-term dynamic models, recent works considered more complex long-term models combined with a global analysis of whole patient data based on nonlinear mixed models, increasing the accuracy of the HIV dynamic analysis. However statistical issues remain, given the complexity of the problem. We proposed to use the SAEM (stochastic approximation expectation-maximization) algorithm, a powerful maximum likelihood estimation algorithm, to analyze simultaneously the HIV viral load decrease and the CD4 increase in patients using a long-term HIV dynamic system. We applied the proposed methodology to the prospective COPHAR2-ANRS 111 trial. Very satisfactory results were obtained with a model with latent CD4 cells defined with five differential equations. One parameter was fixed, the 10 remaining parameters (eight with between-patient variability) of this model were well estimated. We showed that the efficacy of nelfinavir was reduced compared to indinavir and lopinavir.

[1]  H Putter,et al.  A Bayesian approach to parameter estimation in HIV dynamical models , 2002, Statistics in medicine.

[2]  A. Ding,et al.  Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. , 2001, Biostatistics.

[3]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[4]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[5]  Beda Joos,et al.  Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. , 2001 .

[6]  Sophie Donnet,et al.  Estimation of parameters in incomplete data models defined by dynamical systems , 2007 .

[7]  France Mentré,et al.  Benefit of therapeutic drug monitoring of protease inhibitors in HIV‐infected patients depends on PI used in HAART regimen – ANRS 111 trial , 2009, Fundamental & clinical pharmacology.

[8]  Haihong Zhu,et al.  Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models , 2008, Bulletin of mathematical biology.

[9]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[10]  Victor G DeGruttola,et al.  Modelling HIV viral rebound using non‐linear mixed effects models , 2002, Statistics in medicine.

[11]  Xiaohua Xia,et al.  IDENTIFIABILITY OF HIV/AIDS MODELS , 2005 .

[12]  Libin Rong,et al.  Modeling HIV persistence, the latent reservoir, and viral blips. , 2009, Journal of theoretical biology.

[13]  Hélène Jacqmin-Gadda,et al.  Joint modelling of bivariate longitudinal data with informative dropout and left‐censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection , 2005, Statistics in medicine.

[14]  D Commenges,et al.  Maximum Likelihood Estimation in Dynamical Models of HIV , 2007, Biometrics.

[15]  D Commenges,et al.  Practical Identifiability of HIV Dynamics Models , 2007, Bulletin of mathematical biology.

[16]  Hua Liang,et al.  A Note on Conditional AIC for Linear Mixed-Effects Models. , 2008, Biometrika.

[17]  Huldrych F. Günthard,et al.  Quantification of In Vivo Replicative Capacity of HIV‐1 in Different Compartments of Infected Cells , 2001, Journal of acquired immune deficiency syndromes.

[18]  Hulin Wu,et al.  Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance , 2005, Journal of acquired immune deficiency syndromes.

[19]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[20]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[21]  D. Commenges,et al.  Estimation of dynamical model parameters taking into account undetectable marker values , 2006, BMC medical research methodology.

[22]  Julie Bertrand,et al.  Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters , 2008, Journal of biopharmaceutical statistics.

[23]  Russell D. Wolfinger,et al.  Laplace's approximation for nonlinear mixed models. , 1993 .

[24]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[25]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[26]  F. Scholz.  Maximum Likelihood Estimation , 2006 .

[27]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[28]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[29]  Lang Wu.  Exact and Approximate Inferences for Nonlinear Mixed-Effects Models With Missing Covariates , 2004 .

[30]  Hulin Wu,et al.  Hierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System , 2006, Biometrics.

[31]  Marc Lavielle,et al.  Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  R J D B,et al.  Target Cell Limited and Immune Control Models of HIV Infection : A Comparison , 1998 .

[33]  V De Gruttola,et al.  Estimation of HIV dynamic parameters. , 1998, Statistics in medicine.

[34]  David R. Anderson,et al.  Model selection and inference : a practical information-theoretic approach , 2000 .

[35]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[36]  Hulin Wu,et al.  The study of long‐term HIV dynamics using semi‐parametric non‐linear mixed‐effects models , 2002, Statistics in medicine.

[37]  Xiaohua Xia,et al.  Identifiability of nonlinear systems with application to HIV/AIDS models , 2003, IEEE Trans. Autom. Control..

[38]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[39]  J. Hughes,et al.  Mixed Effects Models with Censored Data with Application to HIV RNA Levels , 1999, Biometrics.